1. Anticancer activity of cardiac glycosides
- Author
-
Laurie Menger, Mickaël Michaud, Erika Vacchelli, Guido Kroemer, Yuting Ma, Lorenzo Galluzzi, Oliver Kepp, Isabelle Martins, Laurence Zitvogel, Abdul Qader Sukkurwala, and Sandy Adjemian
- Subjects
Na+/K+ ATPase ,Digoxin ,Digitoxin ,Immunology ,Pharmacology ,HMGB1 ,calreticulin ,Immune system ,immunogenic cell death ,medicine ,Carcinoma ,Immunology and Allergy ,Author's View ,biology ,business.industry ,digoxin ,medicine.disease ,Oncology ,Cancer cell ,biology.protein ,Immunogenic cell death ,business ,digitoxin ,Calreticulin ,medicine.drug - Abstract
Retrospective clinical data indicate that cardiac glycosides (CGs), notably digoxin, prolong the survival of carcinoma patients treated with conventional chemotherapy. CGs are known to influence the immune response at multiple levels. In addition, recent results suggest that CGs trigger the immunogenic demise of cancer cells, an effect that most likely contributes to their clinical anticancer activity.
- Published
- 2012